Lenalidomide for anemia correction in lower-risk del(5q) myelodysplastic syndrome patients of Asian ethnicity

To estimate real-world outcomes in East Asian populations, we conducted a nationwide retrospective analysis of the efficacy and safety of lenalidomide for del(5q) myelodysplastic syndrome (MDS) patients with transfusion-dependent anemia in Korea. Patients aged ≥19 years who had received lenalidomide...

Full description

Saved in:
Bibliographic Details
Published in:Blood research 2021, 56(2), , pp.102-108
Main Authors: Hong, Junshik, Lee, Yoo Jin, Bae, Sung Hwa, Yi, Jun Ho, Park, Sungwoo, Chang, Myung Hee, Park, Young Hoon, Hyun, Shin Young, Chung, Joo-Seop, Jang, Ji Eun, Jung, Joo Young, Jeon, So-Yeon, Song, Seo-Young, Kim, Hawk, Kim, Dae Sik, Kim, Sung-Hyun, Kim, Min Kyoung, Han, Sang Hoon, Park, Seonyang, Kim, Yoo-Jin, Lee, Je-Hwan
Format: Article
Language:English
Subjects:
Original
병리학
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To estimate real-world outcomes in East Asian populations, we conducted a nationwide retrospective analysis of the efficacy and safety of lenalidomide for del(5q) myelodysplastic syndrome (MDS) patients with transfusion-dependent anemia in Korea. Patients aged ≥19 years who had received lenalidomide for the treatment of lower-risk, red blood cell (RBC) transfusion-dependent del(5q) MDS were selected. A filled case report form (CRF) with information from electronic medical records was requested from members of the acute myeloid leukemia (AML)/MDS Working Party of the Korean Society of Hematology. All the CRFs were gathered and analyzed. A total of 31 patients were included in this study. Of 28 evaluable patients, 19 (67.9%) achieved RBC transfusion independence (RBC-TI). Female sex and the development of thrombocytopenia during treatment were associated with achieving RBC-TI. The most common non-hematologic toxicities were pruritus, fatigue, and rashes. All non-hematologic toxicities of grades ≥3 were limited to rash (12.9%) and pruritus (6.5%). Dose reduction was required in 15 of the 19 responders (78.9%). The most common final stable dosing schedule for the responders was 5 mg once every other day (31.6%). Lenalidomide efficacy and tolerability were similar in the Asian del(5q) MDS patients and western patients. Dose reduction during treatment was common, but it was not associated with inferior outcomes.
ISSN:2287-979X
2288-0011
DOI:10.5045/br.2021.2021086